PMID- 19724979
OWN - NLM
STAT- MEDLINE
DCOM- 20091030
LR  - 20181201
IS  - 1439-0795 (Electronic)
IS  - 0176-3679 (Linking)
VI  - 42
IP  - 5
DP  - 2009 Sep
TI  - Oxcarbazepine in combination with Tiaprid in inpatient alcohol-withdrawal--a RCT.
PG  - 175-81
LID - 10.1055/s-0029-1202264 [doi]
AB  - INTRODUCTION: Oxcarbazepine (OXC), a derivative of Carbamazepine (CBZ), may 
      represent a solution to metabolic and side effects of CBZ treatment due to the 
      fact that renal excretion is its major route of elimination. The goal of the 
      study is to compare the efficacy and tolerability of OXC/Tiaprid (TIA) 
      combination therapy to the well established Clomethiazole (CLO) therapy in an 
      inpatient setting. METHODS: To investigate the efficacy of OXC/TIA in terms of 
      lower alcohol withdrawal symptoms and better tolerability, 56 alcohol-dependent 
      patients participated in a randomized open-label trial, where OXC/TIA and CLO 
      treatments were compared. RESULTS: Following admission, we observed that severity 
      of alcohol withdrawal syndrome was comparable between OXC/TIA and CLO-patients. 
      Overall tolerability was good. However, significantly more patients in the 
      OXC/TIA-group (48.1%) displayed no AE compared to the CLO-group (24.1%). We found 
      no significant differences between groups regarding total number of recorded 
      adverse events (AEs). DISCUSSION: OXC/TIA inpatient therapy proved to be as 
      effective and participants demonstrated the same tolerance as with CLO. In 
      medication-based alcohol withdrawal, OXC/TIA could have the potential to become a 
      promising alternative for alcohol dependent patients unable to undergo inpatient 
      withdrawal therapy with CLO. Our findings further indicate that it could be 
      worthwhile testing OXC/TIA in alcohol withdrawal in daily care units and 
      outpatient settings. This is an important question for national health care 
      services, since outpatient therapy is more and more asked for as alternative to 
      inpatient settings.
CI  - Georg Thieme Verlag KG Stuttgart - New York.
FAU - Croissant, B
AU  - Croissant B
AD  - Department of Psychiatry, Psychotherapy and Psychosomatics, Teaching Hospital 
      Sigmaringen, University of Tuebingen, Germany.
FAU - Loeber, S
AU  - Loeber S
FAU - Diehl, A
AU  - Diehl A
FAU - Nakovics, H
AU  - Nakovics H
FAU - Wagner, F
AU  - Wagner F
FAU - Kiefer, F
AU  - Kiefer F
FAU - Mann, K
AU  - Mann K
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20090901
PL  - Germany
TA  - Pharmacopsychiatry
JT  - Pharmacopsychiatry
JID - 8402938
RN  - 0 (Anticonvulsants)
RN  - 0C5DBZ19HV (Chlormethiazole)
RN  - 33CM23913M (Carbamazepine)
RN  - V824N2T753 (Tiapamil Hydrochloride)
RN  - VZI5B1W380 (Oxcarbazepine)
SB  - IM
MH  - Adult
MH  - Alcohol-Related Disorders/*drug therapy
MH  - Anticonvulsants/administration & dosage/adverse effects/*therapeutic use
MH  - Carbamazepine/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Chlormethiazole/adverse effects/therapeutic use
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Inpatients
MH  - Male
MH  - Middle Aged
MH  - Oxcarbazepine
MH  - Substance Withdrawal Syndrome/*drug therapy
MH  - Tiapamil Hydrochloride/administration & dosage/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2009/09/03 06:00
MHDA- 2009/10/31 06:00
CRDT- 2009/09/03 09:00
PHST- 2009/09/03 09:00 [entrez]
PHST- 2009/09/03 06:00 [pubmed]
PHST- 2009/10/31 06:00 [medline]
AID - 10.1055/s-0029-1202264 [doi]
PST - ppublish
SO  - Pharmacopsychiatry. 2009 Sep;42(5):175-81. doi: 10.1055/s-0029-1202264. Epub 2009 
      Sep 1.